Wikipedia -WSS

Wikipedia

author：focus 2025-09-28 01:36:33 - browse：88

The New York Stock Exchange (NYSE) — Spencer Platt/Getty Images

Biohaven Pharmaceuticals said Wednesday that a new type of experimental medicine reduced levels of a disease-causing immune molecule by up to 37% in an early-stage study of human volunteers — a result that the company called “positive” as a proof of concept but that also fell short of investor expectations.

The drug, called BHV-1300, belongs to a new class of antibody medicines that shuttle harmful proteins to the liver so they can be removed from the body. BHV-1300 is specifically designed to reduce levels of an autoantibody called IgG that is implicated in rheumatoid arthritis, myasthenia gravis, and other autoimmune disorders.

In its Phase 1 study, Biohaven tested four escalating doses of BHV-1300 in healthy volunteers, showing a reduction in levels of IgG of 5%, 15%, 30%, and 37%, respectively, the company said. The reductions in IgG levels, which occurred relatively quickly in just four to five days, did not cause significant, adverse changes in liver enzyme levels, Biohaven added — an important safety check given the mechanism of the drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： As AI regulations shape up, health tech startups beg for clarity

hotspot

knowledge

WSS

Sutter Health’s antitrust win overturned by appeals court

CMS got Medicare Advantage quality rating wrong, judge rules

FTC loses bid to block Novant's North Carolina hospital merger

The most pressing bird flu mysteries scientists want answered

In 'major milestone,' FDA approves first cell therapy for solid tumors

ASCO Daily Recap: CAR

Wikipedia

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Medical leaders decry Supreme Court decision on affirmative action

Congress may force more Covid

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Illumina board agrees to spin off Grail, as divestment plans proceed

After affirmative action ruling, medical educators look to 'holistic review'

STAT wants to know your pick for a great summer read or listen

Walensky prepares to leave CDC — and Congress — behind

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Walensky prepares to leave CDC — and Congress — behind

A new initiative will help leaders fight the next pandemic

hotspot

Obamacare plans could cover weight loss drugs

A new initiative will help leaders fight the next pandemic

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

'Little Tech' descents on D.C., wanting a say in how AI is regulated

As AI regulations shape up, health tech startups beg for clarity

ASCO Daily Recap: CAR

hotspot

knowledge

focus

hotspot